trending Market Intelligence /marketintelligence/en/news-insights/trending/w5l6Ny5qyjp_oV3CMw4IXg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Novartis to bolster eye business with Encore Vision acquisition

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Novartis to bolster eye business with Encore Vision acquisition

Novartis AG is acquiring privately held Encore Vision Inc. to add a treatment for presbyopia to its ophthalmology pipeline.

Texas-based Encore Vision is developing EV06, a topical treatment for presbyopia, which is the age-related loss of near-distance vision. More than 80% of adults over the age of 45 develop presbyopia with currently no treatments existing.

Novartis did not disclose the terms of the acquisition, which is subject to customary closing conditions, including regulatory approval.